Insmed Incorporated to Present at the Rodman & Renshaw 3rd Annual Healthcare Conference
12 Mai 2006 - 10:00PM
Business Wire
Insmed, Inc. (Nasdaq: INSM) today announced that the Company will
be presenting at the Rodman & Renshaw 3rd Annual Healthcare
Conference in Monte Carlo. Philip J. Young, Chief Business Officer
of Insmed, will present a corporate overview Monday, May 15, 2006
at 8:40 a.m. CET in the Atlantique Salon of the Le Meridien Beach
Plaza Hotel. A live audio webcast of the presentation will be
available via Insmed's corporate website, www.insmed.com. A replay
of the presentation will be available for approximately 90 days.
About Insmed Incorporated Insmed is a biopharmaceutical company
focused on the development and commercialization of drug candidates
for the treatment of metabolic diseases and endocrine disorders
with unmet medical needs. For more information, please visit
www.insmed.com. The company's leading product, IPLEX was approved
as an orphan drug by the United States Food and Drug Administration
in December 2005 for the treatment of growth failure in children
with severe primary IGF-I deficiency (Primary IGFD) or with growth
hormone (GH) gene deletion who have developed neutralizing
antibodies to GH. About IPLEX IPLEX, a complex of recombinant human
IGF-I and its binding protein IGFBP-3 (rhIGF-I/rhIGFBP-3), is the
only once-daily IGF-I replacement therapy. It is also the only
FDA-approved therapy that provides both IGF-I and IGFBP-3 to treat
children with severe primary IGFD. The drug, to be launched during
the second quarter of 2006, is also being investigated for various
other indications with unmet medical needs, including extreme
insulin resistance, myotonic muscular dystrophy and HIV Associated
Adipose Redistribution Syndrome (HARS). About the Condition Severe
primary IGFD is a genetic or acquired condition in which patients
do not generate sufficient quantities of insulin-like growth
factor-I (IGF-I) due to defect in the growth hormone (GH)
receptor/IGF-I pathway. Gene mutations leading to growth failure
due to IGF-I deficiency have been identified in the growth hormone
receptor, in the GH receptor signalling pathway, and in the IGF-I
gene itself. Patients with severe primary IGFD present with marked
short stature and a poor prognosis for adult stature. Statements
included within this press release, which are not historical in
nature, may constitute forward-looking statements for purposes of
the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release include, but are not limited to, statements regarding
planned clinical trial design, our regulatory and business
strategies, plans and objectives of management and growth
opportunities for existing or proposed products. Such
forward-looking statements are subject to numerous risks and
uncertainties, including risks that product candidates may fail in
the clinic or may not be successfully marketed or manufactured, we
may lack financial resources to complete development of product
candidates, the FDA may interpret the results of our studies
differently than we have, competing products may be more
successful, demand for new pharmaceutical products may decrease,
the biopharmaceutical industry may experience negative market
trends and other risks detailed from time to time in our filings
with the Securities and Exchange Commission. As a result of these
and other risks and uncertainties, actual results may differ
materially from those described in this press release. For further
information with respect to factors that could cause actual results
to differ from expectations, reference is made to our reports filed
by the Company with the Securities and Exchange Commission under
the Securities Exchange Act of 1934, as amended. The
forward-looking statements made in this release are made only as of
the date hereof and Insmed disclaims any intention or
responsibility for updating predictions or financial guidance
contained in this release.
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024